783 related articles for article (PubMed ID: 23769664)
1. Differences in pharmacokinetics and pharmacodynamics of colistimethate sodium (CMS) and colistin between three different CMS dosage regimens in a critically ill patient infected by a multidrug-resistant Acinetobacter baumannii.
Luque S; Grau S; Valle M; Sorlí L; Horcajada JP; Segura C; Alvarez-Lerma F
Int J Antimicrob Agents; 2013 Aug; 42(2):178-81. PubMed ID: 23769664
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand.
Koomanachai P; Tiengrim S; Kiratisin P; Thamlikitkul V
Int J Infect Dis; 2007 Sep; 11(5):402-6. PubMed ID: 17291803
[TBL] [Abstract][Full Text] [Related]
3. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study.
Markou N; Markantonis SL; Dimitrakis E; Panidis D; Boutzouka E; Karatzas S; Rafailidis P; Apostolakos H; Baltopoulos G
Clin Ther; 2008 Jan; 30(1):143-51. PubMed ID: 18343250
[TBL] [Abstract][Full Text] [Related]
4. Urinary Concentrations of Colistimethate and Formed Colistin after Intravenous Administration in Patients with Multidrug-Resistant Gram-Negative Bacterial Infections.
Luque S; Escaño C; Sorli L; Li J; Campillo N; Horcajada JP; Salas E; Grau S
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559275
[TBL] [Abstract][Full Text] [Related]
5. Comparative evaluation of intratracheal colistimethate sodium, imipenem, and meropenem in BALB/c mice with carbapenem-resistant Acinetobacter baumannii pneumonia.
Tang HJ; Chuang YC; Ko WC; Chen CC; Shieh JM; Chen CH; Lee NY; Chiang SR
Int J Infect Dis; 2012 Jan; 16(1):e34-40. PubMed ID: 22088863
[TBL] [Abstract][Full Text] [Related]
6. Colistin treatment in carbapenem-resistant Acinetobacter baumannii pneumonia patients: Incidence of nephrotoxicity and outcomes.
Kwon KH; Oh JY; Yoon YS; Jeong YJ; Kim KS; Shin SJ; Chung JW; Huh HJ; Chae SL; Park SY
Int J Antimicrob Agents; 2015 Jun; 45(6):605-9. PubMed ID: 25772644
[TBL] [Abstract][Full Text] [Related]
7. Aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii pneumonia: experience in a tertiary care hospital in northern Taiwan.
Lin CC; Liu TC; Kuo CF; Liu CP; Lee CM
J Microbiol Immunol Infect; 2010 Aug; 43(4):323-31. PubMed ID: 20688293
[TBL] [Abstract][Full Text] [Related]
8. [Shedding light on the use of colistin: still gaps to be filled].
Luque S; Grau S; Berenguer N; Horcajada JP; Sorlí L; Montero MM; Salas E
Enferm Infecc Microbiol Clin; 2011 Apr; 29(4):287-96. PubMed ID: 21440335
[TBL] [Abstract][Full Text] [Related]
9. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii.
Motaouakkil S; Charra B; Hachimi A; Nejmi H; Benslama A; Elmdaghri N; Belabbes H; Benbachir M
J Infect; 2006 Oct; 53(4):274-8. PubMed ID: 16442632
[TBL] [Abstract][Full Text] [Related]
10. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection.
Cheah SE; Wang J; Nguyen VT; Turnidge JD; Li J; Nation RL
J Antimicrob Chemother; 2015 Dec; 70(12):3291-7. PubMed ID: 26318190
[TBL] [Abstract][Full Text] [Related]
11. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections.
Bassetti M; Repetto E; Righi E; Boni S; Diverio M; Molinari MP; Mussap M; Artioli S; Ansaldi F; Durando P; Orengo G; Bobbio Pallavicini F; Viscoli C
J Antimicrob Chemother; 2008 Feb; 61(2):417-20. PubMed ID: 18174197
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetics and Pharmacodynamics Modeling To Optimize Dosage Regimens of Sulbactam in Critically Ill Patients with Severe Sepsis Caused by Acinetobacter baumannii.
Jaruratanasirikul S; Wongpoowarak W; Wattanavijitkul T; Sukarnjanaset W; Samaeng M; Nawakitrangsan M; Ingviya N
Antimicrob Agents Chemother; 2016 Dec; 60(12):7236-7244. PubMed ID: 27671056
[TBL] [Abstract][Full Text] [Related]
13. [Nebulized colistin treatment of multi-resistant Acinetobacter baumannii pulmonary infection in critical ill patients].
Pérez-Pedrero MJ; Sánchez-Casado M; Rodríguez-Villar S
Med Intensiva; 2011 May; 35(4):226-31. PubMed ID: 21396739
[TBL] [Abstract][Full Text] [Related]
14. Evaluating amikacin dosage regimens in intensive care unit patients: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.
Zazo H; Martín-Suárez A; Lanao JM
Int J Antimicrob Agents; 2013 Aug; 42(2):155-60. PubMed ID: 23756322
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia.
Betrosian AP; Frantzeskaki F; Xanthaki A; Douzinas EE
J Infect; 2008 Jun; 56(6):432-6. PubMed ID: 18501431
[TBL] [Abstract][Full Text] [Related]
16. Dose Optimization of Colistin Combinations against Carbapenem-Resistant Acinetobacter baumannii from Patients with Hospital-Acquired Pneumonia in China by Using an
Bian X; Liu X; Chen Y; Chen D; Li J; Zhang J
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745385
[TBL] [Abstract][Full Text] [Related]
17. Synergy of imipenem/colistin methanesulfonate combinations against imipenem-nonsusceptible multidrug-resistant Acinetobacter baumannii.
Leu HS; Ye JJ; Lee MH; Su LH; Huang PY; Wu TL; Huang CT
J Microbiol Immunol Infect; 2014 Oct; 47(5):406-11. PubMed ID: 23834782
[TBL] [Abstract][Full Text] [Related]
18. [Nosocomial pneumonia caused by multiresistant Acinetobacter baumanii treated by colistin and rifampicin].
Motaouakkil S; Charra B; Hachimi A; Benslama A
Ann Fr Anesth Reanim; 2006 May; 25(5):543-4. PubMed ID: 16488103
[No Abstract] [Full Text] [Related]
19. Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains.
Li J; Nation RL; Owen RJ; Wong S; Spelman D; Franklin C
Clin Infect Dis; 2007 Sep; 45(5):594-8. PubMed ID: 17682994
[TBL] [Abstract][Full Text] [Related]
20. In Vitro Activities of Novel Antimicrobial Combinations against Extensively Drug-Resistant Acinetobacter baumannii.
Córdoba J; Coronado-Álvarez NM; Parra D; Parra-Ruiz J
Antimicrob Agents Chemother; 2015 Dec; 59(12):7316-9. PubMed ID: 26369956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
